FDA Grants Fast Track Designation for Ambrx's ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO - Ambrx Biopharma Inc., Ambrx , today announced that the U.S. Food and Drug Administration has granted Fast Track designation to Ambrx's proprietary anti-PSMA antibody-drug conjugate ...
Source: marketscreener.com